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 Abstract 
Herein we designed a collection of trimethyl-lock quinone profluorophores as activity-based probes for 
imaging NAD(P)H:quinone oxidoreductase (NQO1) in cancer cells and tumour tissues. Profluorophores 
were prepared via synthetic routes from naturally-occurring quinones and characterised in vitro using 
recombinant enzymes, to be further validated in cells and fresh frozen canine tumour tissues as potential 
new tools for cancer detection and imaging. 
 Introduction  
Functional fluorophores1 are powerful tools for early detection of diseases and to enhance the accuracy of 
medical procedures,2 such as fluorescence-guided surgery,3 where new imaging approaches have emerged 
to improve the definition of tumour margins and increase the effectiveness of surgical tissue ressection.4,5 
Fluorescent probes can be also applied ex vivo at the tissue level, providing activity-based readouts of 
enzymes (e.g. proteases) as diagnostic biomarkers or to monitor disease progression over time. Such 
approaches are complementary to immunohistochemistry and in situ hybridisation, commonly used in 
pathology labs, in that they provide direct measurements of protein activity rather than only protein 
expression. In this context, the group of Bogyo recently validated the topical application of fluorescently 
quenched probes for imaging of cathepsin activity in human biopsy samples from cancer patients.6 
Whereas these are extremely valuable tools, there are few chemical fluorophores for monitoring non-
protease enzymatic activity of tumour cells in intact tissues. 
 
NAD(P)H:quinone oxidoreductase 1 (NQO1), also known as DT-diaphorase, is a flavoprotein recognized 
for its ability to carry out a two-electron reduction of various quinones to hydroquinones in the presence 
of the cofactors NADH or NADPH.7 Numerous studies have revealed that solid tumours such as 
cholangiocarcinoma, breast, cervical and lung cancers exhibit drastically higher NQO1 levels than normal 
tissues.8 Therefore, in the recent years, NQO1 has drawn significant attention as a potential biomarker for 
cancer therapy and imaging. One of the main strategies for the development of chemical probes targeting 
NQO1 is the use of trimethyl-lock (TML) quinones to control the release of fluorescent compounds.9 
Profluorophores are constructed where they undergo the two-electron reduction of the quinone moiety by 
NQO1 to release a bright fluorescent reporter via an intramolecular lactonization process (Scheme 1A). 
 
 
 
 
 
 
 
 
  
 
 (A) Detection of DT-diaphorase using trimethyl lock quinone fluorescent structures
(B) This work:
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Scheme 1. (A) General mechanism involving the trimethyl lock system in enzymatic processes. (B) 
Synthetic planning used for the preparation of new TML-quinone systems. 
 
TML-quinone optical probes have been developed including derivatives with rhodamine structures and 
chemiluminescent probes.10 Reported examples, however, do not consider their application in intact tissue 
biopsies, where profluorophores must show: 1) fast cell uptake, 2) high selectivity over related enzymes 
and abundant intracellular biomolecules, 3) rapid activation upon enzymatic reaction, and 4) lack of 
cross-reactivity against abundant biomolecules. Given the structural complexity of most conventional 
fluorescent scaffolds, we have addressed the preparation of new profluorophores considering both 
structural simplification as well as simple synthetic routes. Based on our experience with natural products 
in medicinal chemistry programmes,11 herein we designed a new family of TML-quinone-based 
nitrogenated heterocycles derived from lapachol as activity-based profluorophores for NQO1. The 
chemical design is based on the preparation of fluorescent heterocycles via redox center modification of 
quinoidal systems to render caged compounds which were further conjugated to the TML-quinone 
reactive cores (Scheme 1B). Notably, these compounds can be synthesized in only a few steps from 
available natural products with good recovery yields using simple synthetic routes. 
 
 Results and Discussion 
The synthesis of TML-quinone profluorophores was accomplished by a convergent route, using 
esterification reactions or copper-catalyzed azide-alkyne cycloaddition12 to couple fluorescent 
heterocycles and TMLs. Initially, following the method described by Rohde and co-workers,13  the TML-
quinone 2 was prepared in two steps from the commercially available trimethylhydroquinone 1. With 
compound 2 in hands, the alkyne derivative 3 was readily obtained by condensation in the presence of 
DCC and DMAP (Schemes 2A and S1).14 As for the heterocycles, phenazine (4 and 5) and oxazole (6) 
structures were synthesized from lapachol in good yields by reported methods (Schemes S2-S5).15-16 
Alternatively, Camara and co-workers have recently described a methodology to prepare nor-lapachol 
from lawsone,17 which would allow access to similar phenazine structures. Finally, we generated a small 
collection of TML-quinone profluorophores (7-9) by coupling the TML-quinone moieties 2 and 3 to the 
corresponding heterocycles (Schemes S6-S8). Furthermore, we also generated the non-reactive 
fluorescent heterocycles (4, 10 and 11) bearing a free hydroxyl group instead of the TML-quinone core 
for direct comparative studies (Schemes 2A, S9 and S10). 
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Scheme 2. (A) Example of synthetic route used for the preparation of TML-quinone-based heterocycles. 
(B) Clickable heterocycles 5 and 6 and caged vs uncaged pairs 8 vs 10 and 9 vs 11. 
 First, we examined the spectral properties of the TML-quinone profluorophores 7-9, and compared them 
to their uncaged counterparts (4, 10 and 11, respectively) (Table S1). All 3 profluorophores showed 
significant quenching when compared to the quinone-free structures, with fluorescence increases up to 
200-fold (Figure 1 and Figure S1). This behaviour is likely due to the photoinduced electron transfer 
(PeT) between the fluorescent cores (e.g. phenazine, oxazole) and the TML-quinone moiety, as it has 
been reported for other TML-quinone fluorescent probes.18 Next, we then tested their reactivity against 
recombinant human NQO1 (hNQO1). Compounds 7-9 were incubated with hNQO1 (1 µM) in Tris-HCl 
buffer containing NADH (0.1 mM) at 37 °C, and we measured their fluorescence emission after 30 
minutes. Notably, compounds 7 and 8 exhibited the highest fluorescence amplification, highlighting that 
the phenazine core is better tolerated than the oxazole in the hNQO1 binding pocket. The profluorophores 
also showed a differential behaviour dependent on the linkage between the TML-quinone moiety and the 
phenazine structure, being the short spacer in profluorophore 7 better tolerated than its triazole-based 
counterpart in profluorophore 8. Compound 7 showed a fast response to active hNQO1 (i.e. in the 
presence of its cofactor NADH), reaching 50% of its maximal response only after 10 minutes (Figure 1 
and Figure S2). These results are in agreement with the literature in which the enzyme hNQO1 is only 
active in the the presence of its cofactor NADH.19 
 
In order to confirm that the fluorescence emission of 7 was due to its reaction with hNQO1 and the 
concomitant release of compound 4, we analysed the enzymatic reaction mixture by HPLC-MS and 
confirmed the transformation of the non-fluorescent compound 7 to the fluorescent phenazine (Figure 
S3). Spectroscopic analysis of the pair 4-7 showed absorption and emission maxima wavelengths in the 
blue and green region of the visible spectrum respectively (λabs.: 425 nm; λem.: 490 nm) with a substantial 
Stokes shift (> 60 nm) favourable for live-cell imaging. 
 
Fig 1. (A) Fluorescence fold increase between the pairs of compounds 4-7, 10-8 and 11-9. (B) 
Fluorescence intensity of compounds 7, 8 and 9 upon enzymatic activation by hNQO1 (1 µM) and 
NADH (0.1 mM) for 30 min 37 °C (λexc.: 405 nm, λem.: 490 nm). Data presented as mean values and error 
bars as s.e.m (n=3).  
 Then, we assessed the kinetic parameters defining the enzymatic reaction between the profluorophore 7 
and hNQO1. We plotted the initial rate of formation of the phenazine 4 against different concentrations of 
7 in Tris-HCl buffer at 37 °C (Figure 2), and subsequently determined its maximum rate (Vmax), Michaelis 
constant (Km) and catalyst rate constant (Kcat) (Figure 2). Overall, compound 7 displays a catalytic 
efficiency in the range of 170,000 M-1 min-1, which is in the range or better than most TML-quinone 
fluorescent probes reported to date.10,20 Further experiments were conducted to assess the selectivity of 
the TML-quinone 7 for hNQO1 over related enzymes and intracellular redox biomolecules. In addition to 
incubating 7 with hNQO1 in the presence of NADH, we also assessed its fluorescence response in the 
presence of dicoumarol, a known inhibitor of hNQO1.21 A significant decrease in the fluorescence 
amplification was observed by inhibition of hNQO1, confirming the reactivity of compound 7 against this 
enzyme. We also tested its response against hNQO2, another quinone reductase that can be found in the 
cytosol of mammalian cells and is able to reduce quinone structures.22 Notably, compound 7 showed no 
cross-reactivity with hNQO2, confirming its specificity for hNQO1 (Figure 2). Moreover, we also 
examined whether other biologically-relevant reducing agents could lead to the activation of the 
profluorophore 7. We incubated compound 7 with a large excess of multiple redox biomolecules (e.g. 
NADH, ascorbic acid, L-cysteine and glutathione) and monitored the resulting fluorescence emission. 
Under these conditions, we did not detect any significant fluorescence amplification, proving the 
suitability of compound 7 to specifically monitor the activity of hNQO1 in live cells by fluorescence 
readouts. 
  
Fig 2. (A) Time dependence enzymatic activation assay of compound 7 (50 µM) with hNQO1 (1 µM) 
and NADH (0.1 mM) in Tris-HCl buffer for 30 min at 37 °C (λex: 405 nm, λem: 490 nm). (B) Kinetic 
parameters of compound 7 upon enzymatic activation by hNQ01. (C) Fluorescence fold increase of 
compound 7 (50 µM) after incubation with different enzymes and biomolecules. hNQO1 (1 µM) was 
added with NADH (0.1 mM) and with or without inhibitor [dicoumarol, 100 µM]. hNQO2 was added 
with its cofactor 1-methylnicotinamide (0.1 mM). Other  biomolecules were tested at 1 mM in Tris-HCl 
buffer (λex: 405 nm, λem: 490 nm). Inset) Kinetic plot of the initial rate, V0, against different 
concentrations of compound 7 [5 µM, 7.5 µM, 10 µM, 20 µM, 30 µM and 40 µM]. Data presented as 
mean values and error bars as s.e.m (n=3). ** for p < 0.01.  
 
Encouraged by these results, we employed compound 7 for fluorescence imaging of hNQO1 activity in 
live human cells expressing different levels of the enzyme. Specifically, we used HeLa (human cervical 
cancer) and HL-60 (human leukemia) cell lines due to their reported high expression and low expression 
of hNQO1, respectively.23,24 We acquired fluorescence confocal microscopy images of both cell lines 
under the same experimental conditions (30 min incubation, 37 °C), and observed much brighter signals 
 in the cytosol of hNQO1-positive cells (i.e. HeLa), in line with literature reports describing the cytoplasm 
as the main subcellular region for hNQO1 enzymes (Figure 3).24 Plot profile analysis with the red-
fluorescent counterstain DRAQ5 was used to clarifiy the differential fluorescence intensity of the TML-
quinone 7 in both cell types. Finally, in order to confirm that the intracellular activation of the 
profluorophore 7 was due to its reaction with hNQO1, we pre-incubated HeLa cells with dicoumarol (25 
μM, 1 h) prior to the addition of compound 7. As shown in Figure 3, the blockage of the activity of 
hNQO1 in HeLa cells led to a significant reduction of the fluorescence signal, highlighting the reduction 
of the TML-quinone by active hNQO1 as the main intracellular mechanism for the activation of the 
profluorophore 7 inside cells. 
 
Fig 3. (A-C) Fluorescence microscopy images of HeLa cells (with and without pre-incubation of 
dicoumarol, 25 µM, 1 h) and HL-60 cells after incubation with compound 7 (green, 50 µM) for 30 min at 
37 °C. Nuclei staining was achieved by incubating the cells with DRAQ5 (red, 1 µM). (D) Plot profile 
analysis of the staining of compound 7 (green) and DRAQ5 (red) in HeLa cells (image (A), top) and HL-
60 cells (image c, bottom) as indicated by the yellow line transections. Scale bar: 20 µm. 
 Finally, we used compound 7 for in situ imaging of NQO1 activity in tumour tissues. Fresh frozen canine 
samples from healthy and adenocarcinoma colorectal tissues were thawed and treated with DRAQ5, a 
generic red fluorescent cell marker, and compound 7. Notably, tumour tissues presented brighter green 
fluorescence than healthy tissues. Furthermore, we could confirm that the signal was due to increased 
NQO1 activity by blocking the response of compound 7 with the NQO1 inhibitor dicoumarol (Figure 4). 
 
Fig 4. Fluorescence microscopy images of canine healthy tissue and adenocarcinoma colorectal tissue 
after incubation with DRAQ5 (red) and compound 7 (500 µM, green). Specificity of the green fluorescent 
signal was confirmed by treatment with dicoumarol (100 µM, 1 h). Scale bar: 275 µm. 
 
Experimental 
Materials and apparatus 
Unless otherwise indicated, all common reagents and solvents were used as obtained from commercial 
suppliers without further purification. All commercial chemicals were purchased from Sigma Aldrich. 
Flash column chromatography (FCC) was performed using silica gel (Aldrich 40-63 μm, 230-400 mesh). 
Thin layer chromatography (TLC) was performed using aluminium backed 60 F254 silica plates. 
Visualization was achieved by UV fluorescence. Proton nuclear magnetic resonance spectra (1H NMR) 
were recorded using Bruker DRX 400 or Bruker Avance III 400 MHz, with 5 mm sample tubes, 298 K, 
 digital resolution of 0.01 ppm. Carbon nuclear magnetic resonance spectra (13C NMR) were recorded at 
100 MHz as stated, with 5 mm sample tubes, 298 K, digital resolution of 0.1 ppm. Chemical shifts (δ) are 
given in parts per million (ppm). Peaks are described as singlets (s), doublets (d), double doublets (dd), 
triplets (t), double triplets (dt), and multiplets (m). 1H and 13C NMR spectra were referenced to the 
appropriate residual solvent peak or TMS peak. Coupling constants (J) were quoted to the nearest 0.5 Hz. 
Mass spectra were recorded using a Brüker Daltonics FT-ICRMS Apex 4e 7.0T FT-MS (ESI+ mode) and 
Shimadzu GCMS QP2010+ (EI+ mode). Infrared spectra were recorded on a Perkin Elmer Spectrum One 
FTIR spectrometer as thin films or solids compressed on a diamond plate. Melting points were 
determined using Stuart SMP30 melting point apparatus and are uncorrected. 
 
Synthetic experiments 
Synthesis of 6-hydroxy-4,4,5,7,8-peptamethyl-chroman-2-one. Compound 1’ was prepared according 
to the methodology described by Rohde and co-workers with minor modifications13 from the reaction of 
the 2,3,5-trimethylhydroquinone with 3,3-dimethylacrylic acid and methanesulfonic acid. A mixture of 
the 2,3,5-trimethylhydroquinone (2 g, 13.1 mmol) with 3,3-dimethylacrylic acid (1.45 g, 14.5 mmol) and 
methanesulfonic acid (10 mL) was stirred at 85 °C  for 3 h and then cooled to room temperature. The 
mixture was extracted with CH2Cl2 (2 × 100 mL) and combined organic layer was washed with saturated 
NaHCO3 (3 ×100 mL) and water (3 × 100 mL) and dried over MgSO4. After filtration and evaporation, a 
residue was obtained and recrystallized from hexane and CH2Cl2 (5:1, v/v) to give the desired product as 
a white solid (2.0 g, 8.5 mmol, 65% yield); m.p. 180-182 °C. 1H NMR (400 MHz, CDCl3, 303 K) δ: 4.72 
(s, 1H), 2.55 (s, 2H), 2.37 (s, 3H), 2.23 (s, 3H), 2.19 (s, 3H), 1.46 (s, 6H). 13C NMR (100 MHz, CDCl3, 
303 K) δ: 169.1, 149.0, 143.8, 128.5, 123.7, 122.1, 119.1, 46.3, 35.7, 27.9, 14.6, 12.5, 12.2. Data are 
consistent with those reported in the literature.13 See SI for synthetic route. 
 
Synthesis of 3-methyl-3-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanoic. Compound 2 was 
prepared according to the methodology described by Rohde and co-workers with minor modifications.13 
Compound (1’) (1.58 g, 6.74 mmol) and N-bromosuccinimide (1.26 g, 7.08 mmol) were added to a flask 
containing a mixture of acetonitrile (15 mL) and water (3 mL) and kept under stirring at room 
temperature. After 30 min, solvents were evaporated under reduced pressure. The residue obtained was 
recrystallized from CH2Cl2 and AcOEt (8:1, v/v) to give the desired product as a yellow solid (2.69 g, 
10.8 mmol, 100% yield); m.p. 195-197 °C. 1H NMR (400 MHz, CDCl3, 303 K) δ: 9.25 (s, 1H), 2.99 (s, 
2H), 2.12 (s, 3H), 1.93 (s, 3H), 1.90 (s, 3H), 1.41 (s, 6H). 13C NMR (100 MHz, CDCl3, 303 K) δ: 191.0, 
187.7, 178.6, 152.3, 143.2, 139.2, 138.6, 47.5, 38.2, 29.7, 29.0, 14.5, 12.7, 12.3. Data are consistent with 
those reported in the literature.13 
 Synthesis of prop-2-yn-1-yl-3-methyl-3-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dien-1-yl) 
butanoate. Compound 3 was prepared according to the methodology described by Zhang and co-
workers.14 To a solution of compound 2 (0.400 g, 1.60 mmol) and DCC (0.363 g, 1.76 mmol) in CH2Cl2 
(10 mL) was added DMAP (0.022 g, 0.16 mmol), stirring at room temperature. After 30 min, propargyl 
alcohol (3 equivalents) was added and the mixture was stirred overnight. After reaction finished, the 
mixture was poured onto water and extracted with ethyl acetate (3 × 20 mL). The organic phases were 
combined, dried over Na2SO4, and concentrated under vacuum. The crude product was purified by 
column chromatography and the product 3 was obtained as an oil (70% yield). 1H NMR (400 MHz, 
CDCl3, 303 K) δ: 4.58 (d, J = 2.4 Hz, 2H), 3.02 (s, 2H), 2.41 (t, J = 2.4 Hz, 1H), 2.15 (s, 3H), 1.97 (s, 
6H), 1.45 (s, 6H). 13C NMR (100 MHz, CDCl3, 303 K) δ: 191.0, 187.6, 172.0, 152.2, 143.2, 139.3, 138.7, 
77.7, 74.9, 51.8, 47.5, 38.6, 29.1, 14.5, 12.8, 12.3. EI/HRMS (m/z) [M+H]+: 289.1430. Cald. for 
[C17H21O4]+: 289.1434. 
 
Extraction and purification of the natural product lapachol. Lapachol was initially extracted from the 
heartwood of Tabebuia sp. (Tecoma) and purified by a series of recrystallizations. Initially, nor-lapachol 
was synthesized by Hooker oxidation methodology25 and data are consistent with those reported in the 
literature.26 Nor-lapachol was obtained as an orange solid (160 mg, 0.7 mmol, 70% yield); m.p. 121-122 
°C. 1H NMR (400 MHz, CDCl3, 303 K) δ: 8.13 (ddd, J = 7.5, 1.5 and 0.5 Hz, 1H), 8.10 (ddd, J = 7.5, 1.5 
and 0.5 Hz, 1H), 7.76 (td, J = 7.5, 7.5 and 1.5 Hz, 1H), 7.69 (td, J = 7.5, 7.5 and 1.5 Hz, 1H), 6.03 - 5.99 
(m, 1H), 2.0 (d, J = 1.5 Hz, 3H), 1.68 (d, J = 1.2 Hz, 3H). 13C NMR (100 MHz, CDCl3, 303 K) δ: 184.7, 
181.5, 151.1, 143.6, 134.9, 133.0, 132.9, 129.5, 126.9, 126.0, 120.9, 113.6, 26.5, 21.7. Data are consistent 
with those reported in the literature.26 
 
Synthesis of 3-azido-2,2-dimethyl-2,3-dihydronaphtho[1,2-b]furan-4,5-dione, 3-azido-nor-β-
lapachone. To a solution of nor-lapachol (228 mg, 1.0 mmol) in 25 mL of chloroform, 2 mL of bromine 
was added. The bromo intermediate precipitated immediately as an orange solid. After removal of 
bromine, by adding dichloromethane and then removing the organic solvent with dissolved bromine by 
rotary evaporator, an excess of sodium azide (2 mmol) was added in CH2Cl2 and the mixture was stirred 
overnight. The crude reaction mixture was poured into 50 mL of water. The organic phase was extracted 
with organic solvent, dried over anhydrous Na2SO4, filtered, and evaporated under reduced pressure. The 
azido product was obtained after recrystallization as an orange solid (263 mg, 0.98 mmol, 98% yield); 
m.p. 200-202 °C. 1H NMR (400 MHz, CDCl3, 303 K) δ: 8.14 (ddd, J = 6.9, 2.1 and 0.9 Hz, 1H), 7.72-
7.65 (m, 3H), 4.77 (s, 1H), 1.67 (s, 3H), 1.55 (s, 3H). 13C NMR (100 MHz, CDCl3, 303 K) δ: 180.3, 
175.2, 170.2, 134.5, 132.7, 131.1, 113.5, 129.5, 125.1, 126.7, 95.5, 67.3, 27.1, 21.9. Data are consistent 
 with those reported in the literature.27 Nor-lapachol can be prepared from lawsone as described by 
Camara and co-workers.17 See SI for synthetic route. 
 
Synthesis of 2,2-dimethyl-1,2-dihydrobenzo[a]furo[2,3-c]phenazin-1-ol. Compound 4 was prepared 
following procedure described above. A mixture of the 3-hydroxy-nor-β-lapachone (244 mg, 1.00 mmol), 
sodium acetate (156 mg, 1.90 mmol), ortho-phenylenediamine (119 mg, 1.10 mmol) in 3 mL of glacial 
acetic acid was stirred and monitored by silica gel thin-layer chromatography (TLC). After, the crude 
reaction product was poured into water and the precipitate formed was filtrate and then purified in silica 
gel chromatography, using a mixture of hexane-ethyl acetate, increasing polarity. Compound (4) was 
obtained as a yellow solid (256 mg, 0.81 mmol, 81% yield); m.p. 156-158 °C. 1H NMR (400 MHz, 
CDCl3, 303 K) δ: 9.27 (d, J = 8.0 Hz, 1H), 8.21-8.09 (m, 3H), 7.82 (t, J = 8.0 Hz, 2H), 7.67 (s, 2H), 5.70 
(s, 1H), 4.12 (s, 1H), 1.81 (s, 3H), 1.61 (s, 3H). 13C NMR (100 MHz, CDCl3, 303 K) δ: 140.1, 132.5, 
130.6, 130.1, 130.0, 129.5, 128.4, 127.2, 126.1, 124.8, 123.3, 114.0, 93.8, 27.2, 21.3. EI/HRMS (m/z) 
[M+H]+: 317.1279. Cald. for [C20H17N2O2]+: 317.1285. 
 
Synthesis of 1-azido-2,2-dimethyl-1,2-dihydrobenzo[a]furo[2,3-c]phenazine. Compound 5 was 
prepared according to the classical methodology described by Hooker28 from the reaction of the 3-azido-
nor-β-lapachone with ortho-phenylenediamine. A mixture of the 3-azido-nor-β-lapachone (0.5 mmol), 
sodium acetate (0.95 mmol), ortho-phenylenediamine (0.55 mmol) in 3 mL of glacial acetic acid was 
stirred and monitored by silica gel thin-layer chromatography (TLC). After, the crude reaction product 
was poured into water and the precipitate formed was filtrate and then purified in silica gel 
chromatography, using a mixture of hexane-ethyl acetate, increasing polarity. Compound (5) was 
obtained as a yellow solid (170.5 mg, 0.5 mmol, 100% yield); m.p. 246-248 °C. 1H NMR (400 MHz, 
CDCl3, 303 K) δ: 9.38 (d, J = 8.0 Hz, 1H), 8.29 (dd, J = 7.2 and 1.2 Hz, 1H), 8.21 (dd, J = 7.2 and 1.6 Hz, 
1H), 8.09 (d, J = 7.6 Hz, 1H), 7.86-7.74 (m, 4H), 5.37 (s, 1H), 1.76 (s, 3H), 1.59 (s, 3H). 13C NMR (100 
MHz, CDCl3, 303 K) δ: 159.3, 142.8, 142.7, 141.2, 140.5, 132.9, 130.3, 129.9, 129.5, 128.9, 128.6, 126.2, 
124.5, 123.2, 92.3, 69.9, 27.6, 22.7. EI-HRMS (m/z) [M+H]+ 342.0921. Cald for [C29H23N5OH]+: 
342.1310. 
 
Synthesis of 2-(4-azido-5,5-dimethyl-4,5-dihydrofuro[3',2':3,4]naphtho[1,2-d]oxazol-2-yl)phenol, 
(compound 6). To a solution of 3-azido-nor-β-lapachone (1.0 mmol) in acetic acid (10 mL), 
salicylaldehyde (244 mg, 0.2 mL, 2.0 mmol) was added, and the mixture was heated to 70 ºC; at this 
point, ammonium acetate (1.54 g, 20 mmol) was slowly added, and the temperature was maintained at 
110 ºC. All the reactions were monitored by thin layer chromatography and it was observed that after four 
 hours all the starting material was consumed. At this point, the reaction was cooled to room temperature 
and extracted with dichloromethane and dried with Na2SO4. The solvent was removed under reduced 
pressure to afford the crude product, which was purified on a silica column using a gradient mixture of 
hexane/ethyl acetate as eluent (1% of ethyl acetate in hexane). Compound (6) was obtained as a white 
solid (196 mg, 0.7 mmol, 72% yield); m.p. 169-170 °C. 1H NMR (400 MHz, CDCl3, 303 K) δ: 11.38 (s, 
1H), 8.44 (ddd, J = 8.3, 1.2 and 0.8 Hz, 1H), 8.11 (ddd, J = 8.3, 1.2 and 0.8 Hz, 1H), 7.71 (ddd, J = 8.3, 
7.0 and 1.2 Hz, 1H), 7.55 (ddd, J = 8.3, 7.0 and 1.2 Hz, 1H), 8.06 (ddd, J = 7.9, 1.7 and 0.4 Hz, 1H), 7.42 
(ddd, J = 8.3, 7.3 and 1.7 Hz, 1H), 7.15 (ddd, J = 8.3, 1.1 and 0.4 Hz, 1H), 7.03 (ddd, J = 7.9, 7.3 and 1.1 
Hz, 1H), 5.13 (s, 1H), 1.73 (s, 3H), 1.58 (s, 3H). 13C NMR (100 MHz, CDCl3, 303 K) δ: 160.6, 157.7, 
155.5, 143.2, 132.7, 130.1, 128.6, 126.6, 126.5, 125.4, 123.4, 122.5, 119.7, 119.1, 117.3, 111.1, 102.7, 
91.4, 69.4, 27.4, 22.3. EI/HRMS (m/z) [M+H]+: 373.1285. Cald. for [C21H17N4O3]+: 373.1300. Data are 
consistent with those reported in the literature previously described by our group.16 
 
Synthesis of 2,2-dimethyl-1,2-dihydrobenzo[a]furo[2,3-c]phenazin-1-yl 3-methyl-3-(2,4,5-trimethyl-
3,6-dioxocyclohexa-1,4-dien-1-yl)butanoate, (compound 7). N,N′-Dicyclohexylcarbodiimide (31 mg, 
0.15 mmol) and trimethyl lock quinone (70 mg, 0.2 mmol) were dissolved in 3 mL of CH2Cl2 at 0 ºC 
under stirring until precipitation (20 minutes). Separately, 4-(dimethylamino)pyridine (10 mg, 0.1 mmol) 
and 2,2-dimethyl-1,2-dihydrobenzo[a]furo[2,3-c]phenazin-1-ol (4), (63 mg, 0.2 mmol) were dissolved in 
5 mL of CH2Cl2 under stirring for 20 minutes, then added dropwise for 10 minutes to DCC solution at 0 
ºC. The mixture was heated to 25 °C and keep under stirring for 24 hours. The mixture was extracted with 
CH2Cl2 and water and dried over Na2SO4. Solvent was evaporated under reduced pressure and the crude 
was purified under sílica gel 60 and n-hexane/EtOAc 25:1 to provide compound (7) as a yellow solid 
(66.8 mg, 0.12 mmol, 60% yield); m.p. 205-207 °C. 1H NMR (400 MHz, CDCl3, 303 K) δ: 9.37 (d, J = 
8.0 Hz, 1H), 8.30-8.28 (m, 1H), 8.08 (d, J = 8.0 Hz, 1H), 8.03-8.01 (m, 1H), 7.86-7.74 (m, 4H), 6.65 (s, 
1H), 3.64 (d, J = 16.0 Hz, 1H), 2.47 (d, J = 16.0 Hz, 1H), 1.58 (s, 3H), 1.54 - 1.52 (m, 9H), 1.39 (s, 3H), 
1.28 (s, 3H), 0.97 (s, 3H). 13C NMR (100 MHz, CDCl3, 303 K) δ: 190.6, 185.7, 172.0, 160.1, 151.6, 
142.4, 142.1, 142.0, 140.6, 140.3, 138.3, 137.3, 133.1, 130.1, 130.0, 129.8, 129.5, 128.4, 128.3, 126.3, 
124.2, 122.7, 110.4, 78.3, 48.3, 38.5, 28.4, 28.3, 25.9, 21.0, 13.7, 12.0, 11.0. EI/HRMS (m/z) [M+H]+: 
549.2383. Cald. for [C34H33N2O5]+: 549.2384. 
 
Synthesis of (1-(2,2-dimethyl-1,2-dihydrobenzo[a]furo[2,3-c]phenazin-1-yl)-1H-1,2,3-triazol-4-
yl)methyl 3-methyl-3-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dien-1-yl)butanoate. Compound 8 was 
prepared according to the classical methodology described by Sharpless, Fokin and co-workers with 
minor modification.12 Alkyne (253 mg, 0.87 mmol), CuSO4.5H2O (12 mg, 0.05 mmol) and sodium 
 ascorbate (25 mg, 0.13 mmol) were added to a solution of azido-phenazine (5) (200 mg, 0.58 mmol) in 10 
mL of CH2Cl2:H2O (1:1). The mixture was stirred at room temperature for 24 h and was monitored by 
TLC. The organic phase was extracted with CH2Cl2, dried over sodium sulfate and concentrated under 
reduced pressure. The obtained residue was purified by column chromatography on silica gel, using a 
gradient mixture of hexane/ethyl acetate with increasing polarity as an eluent. Compound (8) was 
obtained as a yellow solid (284 mg, 0.45 mmol, 77% yield); m.p. 286-287 °C. 1H NMR (400 MHz, 
CDCl3, 303 K) δ: 9.45 (d, J = 8.0 Hz, 1H), 8.30-8.28 (m, 1H), 8.20 (d, J = 8.0 Hz, 1H), 8.03-8.00 (m, 
1H), 7.92 (t, J = 7.0 Hz, 1H), 7.77-7.75 (m, 2H), 7.12 (s, 1H), 6.66 (s, 1H), 5.00 (d, J = 13.0 Hz, 1H), 4.96 
(d, J = 13.0 Hz, 2H), 2.90 (d, J = 16.3 Hz, 1H), 2.76 (d, J = 16.3 Hz, 1H), 1.97 (s, 3H), 1.86 (s, 3H), 1.80 
(s, 3H), 1.77 (s, 3H), 1.26 (s, 3H), 1.23 (s, 3H), 1.14 (s, 3H). 13C NMR (100 MHz, CDCl3, 303 K) δ: 
190.9, 187.5, 172.6, 160.5, 152.4, 143.1, 142.9, 142.6, 141.7, 141.1, 140.7, 138.9, 138.5, 133.5, 130.4, 
130.2, 130.2, 129.9, 129.1, 129.0, 126.4, 124.2, 123.4, 123.1, 108.7, 92.9, 69.0, 57.6, 47.4, 38.2, 28.7, 
27.8, 21.7, 14.3, 12.7, 12.2. HRMS (ES+) calculated for C37H35N5O5 [M+H]+: 630.2710; found: 
630.2711. 
 
Synthesis of (1-(2-(2-hydroxyphenyl)-5,5-dimethyl-4,5-dihydrofuro[3',2':3,4]naphtho[1,2-d]oxazol-
4-yl)-1H-1,2,3-triazol-4-yl)methyl-3-methyl-3-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dien-1-
yl)butanoate. Compound 9 was prepared following procedure described above.12 Compound (9) was 
obtained as a yellow oil (184 mg, 0.5 mmol, 80% yield). 1H NMR (400 MHz, CDCl3, 303 K) δ: 11.27 (s, 
1H), 8.50 (d, J = 8.3 Hz, 1H), 8.18 (d, J = 8.3 Hz, 1H), 7.86 (d, J = 8.0 Hz, 1H), 7.80 (t, J = 7.2 Hz, 1H), 
7.65 (t, J = 8.0 Hz, 1H), 7.12 (d, J = 8.3 Hz, 1H), 7.07 (s, 1H), 6.97 (t, J = 8.0 Hz, 1H), 6.48 (s, 1H), 5.02 
(s, 2H), 2.93 (d, J = 16.3 Hz, 1H), 2.82 (d, J = 16.3 Hz, 1H), 2.01 (s, 3H), 1.87 (s, 3H), 1.79 (s, 3H), 1.76 
(s, 3H), 1.27 (s, 3H), 1.23 (s, 3H), 1.21 (s, 3H). 13C NMR (100 MHz, CDCl3, 303 K) δ: 190.9, 187.6, 
172.7, 161.3, 158.0, 156.4, 152.3, 143.4, 143.1, 142.6, 139.0, 138.7, 133.3, 131.0, 129.5, 127.3, 126.9, 
126.2, 123.7, 122.9, 120.0, 119.3, 117.6, 111.0, 101.1, 92.0, 68.6, 57.5, 47.5, 38.3, 28.8, 27.5, 21.5, 14.4, 
12.7, 12.3. EI/HRMS (m/z) [M+H]+: 661.2646. Cald. for [C38H36N4O4]+: 661.2657. 
 
Synthesis of (1-(2,2-dimethyl-1,2-dihydrobenzo[a]furo[2,3-c]phenazin-1-yl)-1H-1,2,3-triazol-4-
yl)methanol. Compound 10 was prepared following procedure described above.12 Compound 10 was 
obtained as a yellow solid (122 mg, 0.36 mmol, 70% yield); m.p. 291-292 °C. 1H NMR (400 MHz, 
DMSO-d6, 303 K) δ: 9.34 (d, J = 7.5 Hz, 1H), 8.30 (dd, J = 3.4 and 6.5 Hz, 1H), 8.16 (d, J = 6.5 Hz, 1H), 
8.03-7.95 (m, 3H), 7.89 (s, 1H), 7.86 (dd, J = 3.4 and 6.5 Hz, 2H), 6.63 (s, 1H), 5.72 (s, 1H), 4.41 (d, J = 
5.6 Hz, 2H), 1.73 (s, 3H), 1.14 (s, 3H). 13C NMR (100 MHz, DMSO-d6, 303 K) δ: 160.4, 148.5, 142.6, 
142.4, 141.2, 140.2, 133.0, 131.5, 131.3, 130.7, 130.2, 129.8, 128.9, 126.4, 124.6, 123.6, 123.6, 110.2, 
 93.5, 68.1, 55.6, 27.6, 21.6. HRMS (ES+) calculated for C23H19N5O2 [M+H]+: 398.1613; found: 
398.1612. 
 
Synthesis of 2-(4-(4-(hydroxymethyl)-1H-1,2,3-triazol-1-yl)-5,5-dimethyl-4,5-
dihydrofuro[3',2':3,4]naphtho[1,2-d]oxazol-2-yl)phenol. Compound 11 was prepared following 
procedure described above.12 Compound (11) was obtained as a white solid (69 mg, 0.18 mmol, 40% 
yield); m.p. 297-298 °C. 1H NMR (400 MHz, DMSO-d6, 303 K) δ: 10.99 (s, 1H), 8.55 (d, J = 8.3 Hz, 
1H), 8.13 (d, J = 8.3 Hz, 1H), 7.92 (s, 1H), 7.86-7.80 (m, 2H), 7.69 (t, J = 7.3 Hz, 1H), 7.45 (t, J = 7.3 Hz, 
1H), 7.11 (d, J = 8.3 Hz, 1H), 7.02 (t, J = 7.3 Hz, 1H), 6.67 (s, 1H), 5.11 (t, J = 5.7 Hz, 1H), 4.48 (d, J = 
5,7 Hz, 2H), 1.72 (s, 3H), 1.13 (s, 3H). 13C NMR (100 MHz, DMSO-d6, 303 K) δ: 160.5, 157.4, 156.1, 
148.9, 143.7, 133.8, 130.5, 129.7, 127.6, 126.8, 126.6, 123.7, 123.6, 123.1, 119.2, 120.7, 117.8, 111.5, 
103.1, 92.5, 67.5, 55.6, 27.5, 21.6. EI/HRMS (m/z) [M+H]+: 429.1563. Cald. for [C24H20N4O4]+: 
429.1557. 
 
Procedures, additional spectroscopy and biological assays. In vitro spectral characterization.  
Spectroscopic data were recorded on a Synergy HT spectrophotometer (Biotek). Compounds were 
dissolved at the indicated concentrations and spectra were recorded at r.t. Spectra are represented as 
means from at least two independent experiments with n = 3. 
 
Enzyme activation assay.  
hNQO1 was purchased from Sigma-Aldrich. Solutions of 50 µM of compounds 7, 8 and 9 were prepared 
in a buffer solution (pH 7.4) containing 25 mM Tris, BSA, Tween-20, 5 μM FAD and 0.1 mM NADH. 1 
µM of hNQO1 was prepared using the same buffer solution and was pre-incubated at 37 °C. 10 µL of 
each compound was added to 10 µL of hNQO1 solution and the experiments were performed in a 384-
well plate at 37 °C. The samples were excited at 405 nm and the fluorescence was collected at 490 nm. 
Fluorescence measurements were collected every 30 seconds for 30 minutes. 
 
Enzyme kinetics.  
Solutions of different concentrations of compound 7 (5 µM, 7.5 µM, 10 µM, 20 µM, 30 µM and 40 µM) 
were prepared in a buffer solution (pH 7.4) containing 25 mM Tris, BSA, Tween-20, 5 μM FAD and 0.1 
mM NADH. 1 µM of hNQO1 was prepared using the same buffer solution and pre-incubated at 37 °C. 
Each assay was performed by adding 10 µL of compound 7 to 10 µL of hNQO1 solution in a 384-well 
plate at 37 °C. The assay was excited at 405 nm and the fluorescence was collected at 490 nm. 
 Fluorescence measurements were collected every 30 seconds for the first 3 minutes. A calibration curve 
was obtained by measuring the fluorescence of different concentrations of the compound 4 in the same 
buffer solution containing hNQO1. A graph of initial rate against concentrations of compound 7 was 
plotted to determine the maximum rate Vmax and Michaelis constant Km by the nonlinear regression (curve 
fit) in GraphPad Prism. 
 
Selectivity assays.  
Solutions of 50 µM of compound 7 were prepared in a buffer containing 25 mM Tris pH 7.4, 6 mg/100 
ml BSA, 10 μl/100 ml Tween-20, 5 μM FAD, 0.1 mM NADH. 1 µM of hNQO1 was prepared using the 
same buffer and was pre-incubated with dicoumarol (100 µM) at 37 °C for 1 h. 10 µL of compound 7 was 
added to 10 µL of hNQO1 solution and the experiments were performed in a 384-well plate at 37 °C. 1 
mM solutions of known redox biomolecules (Glutathione, L-Ascorbate, L-Cysteine) were prepared using 
the same buffer solution and were pre-incubated at 37 °C for 30 min. All selectivity assays were 
performed with excitation at 405 nm and the fluorescence measurements were collected at 490 nm. 
 
Fluorescence microscope live-cell imaging. 
Human HeLa (ATCC CCL-2) and HL-60 (ATCC CCL-240) cells were grown using Dulbecco’s 
Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS), antibiotics (100 U 
mL-1 penicillin and 100 mg mL-1 streptomycin) and 2 mM L-glutamine in a humidified atmosphere at 37 
°C with 5% CO2. Cells were regularly passaged in T-75 cell culture flasks. For microscopy experiments, 
cells were plated on glass chamber slides Lab-Tek™ II (Nunc) the day before imaging, reaching 75% to 
90% confluence on the day of the experiment. For imaging experiments, a solution of 50 µM of 
compound 7 were prepared in PBS containing 5 µM of DRAQ5. Cells were incubated for 30 min at 37 °C 
with 200 µL of solution containing compound 7 and DRAQ5 as indicated, washed once with 200 µL of 
PBS and imaged under a EVOS FL2 fluorescence microscope using a 40X objective. Microscopy images 
were analysed and processed with ImageJ. 
 
Ex vivo tissue imaging.  
Tissue experiments were approved by the Veterinary Ethical Review Committee (VERC, reference 
number 126.18). Canine colorectal adenocarcinoma and healthy colon tissues were snap frozen at -80 °C 
and cut into 6 µm-thick slices. Upon thawing, tissues were air dried for 20-30 minutes at r.t. and placed in 
a glass coplin jar for fixation in ice cold acetone (10 min). Afterwards, tissues were air dried at r.t. and a 
hydrophobic circle was drawn around the tissue section with a PAP pen. Tissues were then rehydrated in 
 PBS (3 x 5 min) at r.t, treated with 0.1% Triton X-100 in PBS for 5 min at r.t, washed with PBS (3 x 5 
min) at r.t, and incubated with DRAQ5 (5 µM) and dicoumarol (100 µM, 100 µL) for 1 h when 
applicable. Next, tissues were washed with PBS (3 x 5 min) at r.t, and incubated with compound 7 (500 
µM, 100 µL) and NADH (0.1 mM, 100 µL) for 1 h at 37 °C in the dark. After a final washing with PBS 
(3 x 5 min) at r.t, coverslips were mounted in ProLong Gold and tissues were imaged under a EVOS FL2 
fluorescence microscope using a 10X objective. Microscopy images were analyzed with ImageJ. 
 
Conclusions  
In summary, we have developed a small collection of new trimethyl-lock profluorophores from naturally-
occurring quinones as activity-based probes for NQO1. The phenazine derivative 7 showed rapid and 
selective fluorescence activation upon reaction with NQO1 but not with other biomolecules or closely-
related enzymes. Furthermore, we validated compound 7 for in situ fluorescence imaging of NQO1 
activity in cancer cells and fresh frozen canine tumour tissues. 
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